AstraZeneca Licenses Preclinical NASH Candidate from Partner Ionis
By Heather Cartwright
Pharma Deals Review: Vol 2018 Issue 4 (Table of Contents)
Published: 20 Apr-2018
DOI: 10.3833/pdr.v2018.i4.2321 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In the latest deal in the crowded non-alcoholic steatohepatitis (NASH) field, AstraZeneca has licensed a preclinical antisense drug candidate from Ionis Pharmaceuticals for US$30 M upfront and up to US$300 M in development and regulatory milestone payments...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS